Fibroblast growth factor receptor (FGFR)-selective tyrosine kinase inhibitors (TKI), such as infigratinib, show potency and selectivity for FGFR3 at pharmacologically 'relevant doses for the potential treatment of achondroplasia (ACH)

被引：0
|
作者：
Dobscha, Katherine [1 ]
Wei, Ge [1 ]
Dambkowski, Carl [1 ]
Rogoff, Daniela [1 ]
机构：
[1] QED Therapeut Inc, San Francisco, CA USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-726
引用
收藏
页码：273 / 273
页数：1
相关论文
共 41 条
  • [31] Discovery of novel pyrido[2,3-b]pyrazine as fibroblast growth factor receptor (FGFR-1, 2, 3 & 4) kinase inhibitors with nanomolar affinity
    Angibaud, P.
    Querolle, O.
    Berdini, V.
    Saxty, G.
    Cleasby, A.
    Colombel, H.
    Csoka, I.
    Gilissen, R.
    King, P.
    Meerpoel, L.
    Paulussen, C.
    Pilatte, I.
    Poncelet, V.
    Rees, D. C.
    Roux, B.
    Tronel, V.
    Verhulst, T.
    Wroblowski, B.
    Murray, C. W.
    Vialard, J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 115 - 115
  • [32] Genomic profiling by cell-free circulating tumor DNA in patients with recurrent adenoid cystic carcinoma (ACC) and the potential activity of selective fibroblast growth factor receptor (FGFR) inhibitors.
    Perez, Cesar Augusto
    Dutcher, Giselle
    Sargi, Zoukaa
    Guevara, Nelson
    Tse, David
    Benedetto, Pasquale W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
    Trudel, Suzanne
    Bergsagel, P. Leif
    Singhal, Seema
    Niesvizky, Ruben
    Comenzo, Raymond L.
    Bensinger, William I.
    Lebovic, Daniel
    Choi, YounJeong
    Lu, Dan
    French, Dorothy
    Penuel, Elicia
    Ho, William
    Stewart, Keith
    BLOOD, 2012, 120 (21)
  • [34] Optimization of novel pyrido[2,3-b]pyrazine based small molecule fibroblast growth factor receptor 1, 2, 3 & 4 (FGFR) inhibitors into a potential clinical candidate
    Dey, N.
    De, P.
    Leyland-Jones, B.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 128 - 128
  • [35] 1-oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase
    Barvian, MR
    Panek, RL
    Lu, GH
    Kraker, AJ
    Amar, A
    Hartl, B
    Hamby, JM
    Showalter, HDH
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (22) : 2903 - 2908
  • [36] FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
    Raphael, Ari
    Dudnik, Elizabeth
    Hershkovitz, Dov
    Jain, Suyog
    Olsen, Steve
    Soussan-Gutman, Lior
    Ben-Shitrit, Taly
    Dvir, Addie
    Nechushtan, Hovav
    Peled, Nir
    Onn, Amir
    Agbarya, Abed
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
  • [37] Identification of protein kinase fibroblast growth factor receptor 1 (FGFR1) inhibitors among the derivatives of 5-(5,6-dimethoxybenzimidazol-1-yl)-3-hydroxythiophene-2-carboxylic acid
    Galyna Volynets
    Sergiy Lukashov
    Iryna Borysenko
    Andrii Gryshchenko
    Sergiy Starosyla
    Volodymyr Bdzhola
    Tetiana Ruban
    Anna Iatsyshyna
    Lyubov Lukash
    Yaroslav Bilokin
    Sergiy Yarmoluk
    Monatshefte für Chemie - Chemical Monthly, 2019, 150 : 1801 - 1808
  • [38] Identification of protein kinase fibroblast growth factor receptor 1 (FGFR1) inhibitors among the derivatives of 5-(5,6-dimethoxybenzim idazol-1-yl)-3-hydroxythiophene-2-carboxylic acid
    Volynets, Galyna
    Lukashov, Sergiy
    Borysenko, Iryna
    Gryshchenko, Andrii
    Starosyla, Sergiy
    Bdzhola, Volodymyr
    Ruban, Tetiana
    Iatsyshyna, Anna
    Lukash, Lyubov
    Bilokin, Yaroslav
    Yarmoluk, Sergiy
    MONATSHEFTE FUR CHEMIE, 2019, 150 (10): : 1801 - 1808
  • [39] Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors
    Bao, Yilin
    Gabrielpillai, Jennis
    Dietrich, Joern
    Zarbl, Romina
    Strieth, Sebastian
    Schroeck, Friederike
    Dietrich, Dimo
    CLINICAL EPIGENETICS, 2021, 13 (01)
  • [40] Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors
    Yilin Bao
    Jennis Gabrielpillai
    Jörn Dietrich
    Romina Zarbl
    Sebastian Strieth
    Friederike Schröck
    Dimo Dietrich
    Clinical Epigenetics, 2021, 13
12345